Blastic plasmacytoid dendritic cell neoplasm: A single-center experience

Annals of Hematology

Volumn 92, Issue 3, 2013, Pages 351-356

  An, Ho Jung ^a   Yoon, Dok Hyun ^a   Kim, Shin ^a   Shin, Su Jin ^b   Huh, Jooryung ^b   Lee, Kyoo Hyung ^b   Suh, Cheolwon ^a  

^a University of Ulsan   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Blastic plasmacytoid dendritic cell neoplasm; Case series; Cutaneous involvement

Indexed keywords

ASPARAGINASE; CARMUSTINE; CD123 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; VINCRISTINE;

ADULT; ANTIGEN DETECTION; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL MALIGNANCY; BLOOD; BONE MARROW TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LYMPHOMA; MALE; OVERALL SURVIVAL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SKIN TUMOR; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; BONE MARROW NEOPLASMS; DATABASES, FACTUAL; DENDRITIC CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84873999749     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1614-z     Document Type: Article

References (21)

1. Herling M, Jones D (2007) CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 127(5):687-700. doi: 10.1309/fy6pk436nbk0ryd4
2. Facchetti FJD, Petrella T (2008) Blastic plasmacytoid dendritic cell neoplasm. WHO classification of tumors of haematopoietic and lymphoid tissues. IARC, Lyon
3. Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, Orfeuvre H, Corront B, Feuillard J, Sotto JJ, Bensa JC, Briere F, Plumas J, Jacob MC (2001) Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97(10):3210-3217
4. Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M, Meijer CJ, Courville P, Joly P, Grange F, De Muret A, Machet L, Dompmartin A, Bosq J, Durlach A, Bernard P, Dalac S, Dechelotte P, D'Incan M, Wechsler J, Teitell MA (2005) Blastic NK-cell lymphomas (agranular CD4+CD56+hematodermic neoplasms): a review. Am J Clin Pathol 123(5):662-675
5. Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, Metze D, Fink-Puches R, Wiesner T, Cerroni L (2010) Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 34(1):75-87. doi: 10.1097/PAS. 0b013e3181c5e26b
6. Argyrakos T, Rontogianni D, Karmiris T, Kapsimali V, Grigoriou E, Tsantekidou M, Naum C, Galani V, Pantelidaki C, Harhalakis N, Nikiforakis E, Kanavaros P (2004) Blastic natural killer (NK)-cell lymphoma: report of an unusual CD4 negative case and review of the CD4 negative neoplasms with blastic features in the literature. Leukemia & Lymphoma 45(10):2127-2133. doi: 10.1080/10428190410001723232
7. Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E, Jacob MC, Salaun V, Arock M, Drenou B, Schillinger F, Seilles E, Tiberghien P, Bensa JC, Plumas J, Saas P (2005) Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood 105(3):1256-1264. doi: 10.1182/blood-2004-06-2416
8. Petrella T, Teitell MA, Spiekermann C, Meijer CJ, Franck F, Enache I (2004) A CD56-negative case of blastic natural killer-cell lymphoma (agranular CD4+/CD56+ haematodermic neoplasm). Br J Dermatol 150(1):174-176
9. Reimer P, Rudiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A, Konrad Muller-Hermelink H, Wilhelm M (2003) What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplantation 32(7):637-646. doi: 10.1038/sj.bmt.1704215
10. Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drenou B, Duchayne E, Falkenrodt A, Garand R, Homolle E, Husson B, Kuhlein E, Le Calvez G, Sainty D, Sotto MF, Trimoreau F, Bene MC (2002) Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 99(5):1556-1563
11. Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, Jaffe ES (2010) Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematol 95(11):1873-1879. doi: 10.3324/haematol.2010.026179
12. Inoue D, Maruyama K, Aoki K, Nagano S, Maruoka H, Imai Y, Ito K, Ishikawa T, Takahashi T (2011) Blastic plasmacytoid dendritic cell neoplasm expressing the CD13 myeloid antigen. Acta Haematologica 126(2):122-128. doi: 10.1159/000328180
13. Tsagarakis NJ, Kentrou NA, Papadimitriou KA, Pagoni M, Kokkini G, Papadaki H, Pappa V, Marinakis T, Anagnostopoulos NI, Vadikolia C, Anagnostopoulos A, Angelopoulou MK, Terpos E, Poziopoulos C, Anargyrou K, Rontogianni D, Papadaki T, Psarra A, Kontopidou FN, Skoumi D, Papadhimitriou SI, Paterakis G (2010) Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the hellenic dendritic cell leukemia study group. Leuk Res 34(4):438-446. doi: 10.1016/j.leukres.2009.09.006
14. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadie M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, Macintyre E, Bene MC, Saas P, Jacob MC (2009) Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 145(5):624-636. doi: 10.1111/j.1365-2141.2009.07679.x
15. Petrella T, Facchetti F (2010) Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009? Autoimmun 43(3):210-214. doi: 10.3109/08916930903510898
16. Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dompmartin A, D'Incan M, Maubec E, Grange F, Dereure O, Prey S, Barete S, Wetterwald M, Fraitag S, Petrella T (2010) Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 162(1):74-79. doi: 10.1111/j.1365-2133.2009.09373.x
17. Suzuki R, Nakamura S, Suzumiya J, Ichimura K, Ichikawa M, Ogata K, Kura Y, Aikawa K, Teshima H, Sako M, Kojima H, Nishio M, Yoshino T, Sugimori H, Kawa K, Oshimi K (2005) Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer 104(5):1022-1031. doi: 10.1002/cncr.21268
18. Li Y, Li Z, Lin HL, Chen XH, Li B (2011) Primary cutaneous blastic plasmacytoid dendritic cell neoplasm without extracutaneous manifestation: case report and review of the literature. Pathol Res Pract 207(1):55-59. doi: 10.1016/j.prp.2010.05.008
19. Bekkenk MW, Jansen PM, Meijer CJ, Willemze R (2004) CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 15(7):1097-1108. doi: 10.1093/annonc/mdh268
20. Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP (2007) Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 109(4):1720-1727. doi: 10.1182/blood-2006-04-018143
21. Jaye DL, Geigerman CM, Herling M, Eastburn K, Waller EK, Jones D (2006) Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. Mod Pathol 19(12):1555-1562. doi: 10.1038/modpathol.3800679